Effect of hepatic arterial infusion chemotherapy combined with pro-grammed death receptor 1 antibody and Renvastinib in the treatment of advanced liver cancer complicated with portal vein cancer thrombus
Objective To investigate the clinical efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed death receptor 1(PD-1)antibody and lenvastinib in the treatment of advanced liver cancer complicated with portal vein cancer thrombus.Methods A retrospective analysis was performed on 21 patients with advanced liver can-cer with portal vein thrombus who received hepatic arterial infusion chemotherapy combined with PD-1 antibody and Ren-vastinib in Pingxiang People's Hospital from December 2020 to May 2023.All patients received hepatic arterial infusion chemotherapy,immunization and targeted therapy.Overall survival,progression-free survival,overall response rate and dis-ease control rate were counted.Adverse events during treatment and follow-up were recorded.Results After treatment,0 cases had complete response,7 cases had partial response,11 cases had stable disease,and 3 cases had progressive dis-ease.The overall response rate was 38.45％,and the disease control rate was 85.71％.The median alpha-fetoprotein(AFP)level was 184.07(9.44,7 103.85)ng/ml,and the median AFP level before treatment was 553.28(50.43,11 542.05)ng/ml,which was lower after treatment than before treatment,and the difference was statistically significant(P＜0.05).The median follow-up time was 12.71 months(4-24)months.The overall survival time was 89.2％at 6 months and 63.1％at 12 months.The median overall survival time was not reached.The 6-month progression-free survival was 70.38％,and the median pro-gression-free survival was 9.48 months(95％CI:7.26-11.72).The common grade 1 to 2 adverse events were hypertension,fatigue,and elevated glutamic-pyruenic aminotransferase,among which 16 cases of grade 3 adverse events were recovered by symptomatic treatment before the next cycle of treatment.Conclusion Hepatic artery infusion chemotherapy combined with PD-1 antibody and Renvastinib in the treatment of advanced liver cancer with portal vein cancer thrombus has good tumor responsiveness,and the adverse reactions in the treatment process are controllable.
Hepatic arterial infusion chemotherapyProgrammed death receptor 1 antibodyRenvastinibAdvanced liver cancerPortal vein cancer thrombus
维普
万方数据
